SUN PHARMA - walk in drives for Freshers & Experienced Candidates on 26th May 2019.
About Sun Pharma:-
If we are very important with a property, then it is quality. Quality is considered paramount in all the places where quality is assessed, developed, produced, tested and delivered. Our operations are run by the best technology and processes that are strictly governed by all types of strict regulatory approvals. Our commitment to implementing a strong global quality management system is based on our determination to fulfill the expectations of all stakeholders including patients, consumers and regulators and to maintain the culture of diligence to work. In this way, your quality goes beyond business and legal requirements. It is your ideal to keep the patients first.
Our World Quality Management Team ensures that each product that is manufactured and distributed abides by the best practices and quality, integrity, efficiency and security adopted by us at international level.
To maintain the quality standard, each plant has a definite defined process and system, following the requirements of Current Good Manufacturing Practices (CGMP), WHO, PIC and EU GMP, to ensure that our operating process meets extremely poor standards. Regulators like US FDA, EMA, HC, WHO and TGA
By strict adherence to the quality system and procedures, there are trained personnel on every site for quality check with the Regulatory Case Department. The team is guided by the Corporate Quality Unit (sequo). The CAC ensures that the latest updates to GMP are being updated in the guidelines, Standard Operating System (SOP) and protocols. These guidelines are implemented to deliver quality products timely. In addition, production projects are monitored by an autonomous Corporate Compliance Department to ensure 24 x 7 compliance and compliance.
Quality goes beyond our unbelief commitment itself. We urge that our business partners follow national and international regulatory and professional standards that are in our own alignment. Our own quality standards have consistently been benchmarked to world best practices. This means they have been updated to keep it running continuously with increasing mobility in the global environment.
We are committed to high quality standards and will ensure that all our facilities, offices and legal bodies match the ideal standards expected by the global pharmaceutical company.
We were pioneers in Indian Pharmaceutical companies to see the huge value of investment in R & D. Our initial investment in R & D three decades ago, enables us to make our main difference in technology and to develop a strong product basket for different markets around the world. Formulations, process chemistry, and our focus on enhancing our excellent ability in the development of generic and technically complex products by the focusing teams in analytical development. You have the ability to distribute quality products in a set of timelines established at a lower cost and without compromise on quality.
There are about 2000 research scientists working on multiple R & D centers capable of state-of-the-art technology for research. It is difficult to create our scientists for generic development, technology-intensive products, active pharmaceutical ingredients (APIs), new drug delivery systems (NDS) and new chemical companies (NCE).
Our ability develops development of nuclear products, in addition to developing liposomal products, inhalers, leoflised injections, nasal spray, and controlled release dosage form.
Our information in Pharmaceutical Research allows for quick ramp-up of various range of instant and new delivery systems in oral, parental, topical and inhalation dosage forms. Our formulation expert is in the area of taste masking, spray-drying, drug leveling, nano-milling, lifefillation and other pharmaceutical unit operations, which enables us to meet different formulation design requirements and concepts. The ability to develop a complex API, using a sophisticated technology to create a difficult-to-computer, is a major component of our research.
To develop new scientific concepts and ideas, our scientists work closely with our professional development team to absorb the market needs of the therapeutic sector and the colleagues. According to research, we invest 7-8 percent of your income every year. In the same way, we constantly monitor the research potential of focusing on developing new technologies. Indian general companies have the highest R & D productivity.
For many years we have developed experts in the field of pharmacokinetic and bioequalvans to facilitate generic or branded generic medicines for international markets. Our 408-bed clinical pharmacology unit works on biological / biogevelopment studies in GCP compliance with expert staffers. Phase is a full-site facility for the first clinical studies. Our CPU has been inspected by US FDA, ANTISIA, MHRA and DCGI.
Our research strategies and implementation have been done by a good intellectual property team that has experience and experience of chemistry, analytical techniques, dosage form and global patent law. In the past 10 years, we have been consistently successful in challenging patents with first-to-file specifications under the Hatch-Waxman Act in America and have helped bring such a cheap, high-quality version of such products. Otherwise market as quickly as possible.
Our ability to research does not only give us rich dividends in terms of business but also gives us a tremendous reputation for quality and ability. The most amazing evidence came when the US FDA permitted us to import liposomal doxorbicin, which was not allowed. In US and Europe, we are among the few general companies in products like Azellstein Nasal Spray and Sumatripten Autoinjictor.
Our F & D centers have been inspected and approved by the International Regulatory Authority including the US FDA and European authorities.
We have ensured world-class quality in design, equipment and operations across all our manufacturing facilities around the world. We have 40 (APIs and full doses) of the latest cutting-edge products in 6 continents.
Our manufacturing activities focus on creating genics, branded generic, specialty, over-the-counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical materials (APIs) and intermediates, including tablets, capsules, injectionsbles, cream, cream And fluid We produce specialized APIs with controlled substances, steroids, peptides and anti-cancer.
We are a very skilled team of regulatory issues experts who are well known with regulatory policies and procedures. In terms of timely submission to the authorities, they have a lot of experience in handling the regulatory queries by officials and customers.
A broad range of regulatory agencies regularly perform strict audits to comply with our production facilities (CGMP). Many regulatory agencies including the FDA-USA, EMA-Europe, MHRA-UK, MCC-South Africa, TGA-Australia, Anvilia-Brazil, WHO-Geneva, BFARM-Germany, KFDA-Korea and PMDA-Japan have examined our facilities.
